[HTML][HTML] Adalimumab with or without methotrexate in juvenile rheumatoid arthritis

…, D Elewaut, I Foeldvari, V Gerloni… - … England Journal of …, 2008 - Mass Medical Soc
Background Tumor necrosis factor (TNF) has a pathogenic role in juvenile rheumatoid
arthritis. We evaluated the efficacy and safety of adalimumab, a fully human monoclonal anti …

Abatacept in children with juvenile idiopathic arthritis: a randomised, double-blind, placebo-controlled withdrawal trial

…, C Abud-Mendoza, R Burgos-Vargas, V Gerloni… - The Lancet, 2008 - thelancet.com
Background Some children with juvenile idiopathic arthritis either do not respond, or are
intolerant to, treatment with disease-modifying antirheumatic drugs, including anti-tumour …

A randomized, placebo‐controlled trial of infliximab plus methotrexate for the treatment of polyarticular‐course juvenile rheumatoid arthritis

…, MT Apaz, E Baildam, A Fasth, V Gerloni… - … : Official Journal of …, 2007 - Wiley Online Library
Objective To evaluate the safety and efficacy of infliximab in the treatment of juvenile
rheumatoid arthritis (JRA). Methods This was an international, multicenter, randomized …

A randomized trial of parenteral methotrexate comparing an intermediate dose with a higher dose in children with juvenile idiopathic arthritis who failed to respond to …

N Ruperto, KJ Murray, V Gerloni… - … : Official Journal of …, 2004 - Wiley Online Library
Objective To compare the safety and efficacy of parenteral methotrexate (MTX) at an
intermediate dosage (15 mg/m2/week) versus a higher dosage (30 mg/m2/week) in patients …

Localized scleroderma in childhood is not just a skin disease

…, J Chaitow, J Ros, MT Apaz, V Gerloni… - Arthritis & …, 2005 - Wiley Online Library
Objective Juvenile localized scleroderma is usually considered a disease that is confined to
the skin and subcutaneous tissue. We studied the prevalence and clinical features of …

Long‐term outcome and prognostic factors of juvenile dermatomyositis: a multinational, multicenter study of 490 patients

…, M Alessio, MG Alpigiani, V Gerloni… - Arthritis Care & …, 2010 - Wiley Online Library
Objective To investigate the long‐term outcome and prognostic factors of juvenile
dermatomyositis (DM) through a multinational, multicenter study. Methods Patients consisted …

Anti-CD 20 monoclonal antibody (rituximab) treatment for inflammatory ocular diseases

…, G Modorati, M Gattinara, PL Meroni, V Gerloni - Autoimmunity …, 2011 - Elsevier
Rituximab is a monoclonal antibody directed against the CD20 antigen expressed on B cells
and widely used in the treatment of non-Hodgkin's lymphoma and rheumatoid arthritis …

Prednisone versus prednisone plus ciclosporin versus prednisone plus methotrexate in new-onset juvenile dermatomyositis: a randomised trial

…, T Avcin, K Brochard, F Corona, F Dressler, V Gerloni… - The Lancet, 2016 - thelancet.com
Background Most data for treatment of dermatomyositis and juvenile dermatomyositis are
from anecdotal, non-randomised case series. We aimed to compare, in a randomised trial …

Long‐term safety and efficacy of abatacept in children with juvenile idiopathic arthritis

…, R Burgos‐Vargas, V Gerloni… - Arthritis & …, 2010 - Wiley Online Library
Objective We previously documented that abatacept was effective and safe in patients with
juvenile idiopathic arthritis (JIA) who had not previously achieved a satisfactory clinical …

Methotrexate treatment in juvenile localized scleroderma: a randomized, double‐blind, placebo‐controlled trial

…, M Alessio, FL Torre, RA Podda, V Gerloni… - Arthritis & …, 2011 - Wiley Online Library
Objective Juvenile localized scleroderma is a chronic progressive fibrotic disorder of the skin
that causes permanent disability and aesthetic damage. This study was undertaken to …